FDA Clearance Tracker · K171401
ELITech Clinical Systems BILIRUBIN TOTAL 4+1, ELITech Clinical Systems BILIRUBIN DIRECT 4+1
Last checked: Nov 20, 2026Latest source record: Jul 11, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jul 11, 2017
Substantially Equivalent
Time to decision
60 days
Received May 12, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K171401
- Device name
- ELITech Clinical Systems BILIRUBIN TOTAL 4+1, ELITech Clinical Systems BILIRUBIN DIRECT 4+1
- Applicant
- Elitechgroup
- Applicant location
- Sees, FR
- Received
- May 12, 2017
- Decided
- Jul 11, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Diazo Colorimetry, Bilirubin (CIG)
- Device class
- Class II
- Regulation
- 21 CFR 862.1110
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code CIG. The earliest in FDA's data is K760479, decided Oct 29, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K171401
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Elitechgroup
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K180559 · Decided Oct 29, 2018 · 242 days after receipt
Device type: Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples (PGI) · Laboratory Medicine & Pathology
K180627 · Decided Jul 27, 2018 · 140 days after receipt
Device type: Device, Iontophoresis, Specific Uses (KTB) · Physical Medicine & Rehabilitation
K153644 · Decided Sep 7, 2016 · 261 days after receipt
Device type: Hexokinase, Glucose (CFR) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.